Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Organon & Co. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Organon & Co. filed a Form 8-K report on November 5, 2024, announcing the FDA extended the target action date for VTAMA® cream review to March 12, 2025, from December 12, 2024, without concerns on safety and efficacy.
Menopause Treatment Market 2034: Clinical Trials, EMA, PDMA
DelveInsight's Menopause Market Insights, Epidemiology, and Market Forecast-2034 report analyzes market trends, epidemiology, and emerging therapies in the US, EU4, UK, and Japan. Key companies include GlaxoSmithKline, Pfizer, Bayer, and others. The market size was ~USD 10,968 million in 2022, with hormonal therapy dominating but expected to decline as non-hormonal therapies gain prevalence. Notable therapies include VEOZAH, a non-hormonal treatment approved by the FDA in 2023.
© Copyright 2024. All Rights Reserved by MedPath